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Background: Up to 50% of pediatric patients with Crohn´s disease (CD) report oral manifestations, 
but less is known about their oral health when they become adults.  
Goals: Our aim was to provide detailed descriptions of the presence of oral and 
otorhinolaryngological manifestations in pediatric onset CD patients once they reached adulthood, 
to look for predisposing factors and to compare the findings to matched controls.  
Study: Adult patients diagnosed with CD in childhood at the Children´s Hospital, University of 
Helsinki, Finland, after 2000 were invited for a follow-up appointment in 2016 and 24 were 
examined by a dentist and otorhinolaryngologist. They were compared with 22 matched controls 
from the Population Register Centre. The participants completed questionnaires about their general 
health, any special diets and their health-related quality of life (HRQoL). Their nutrition was 
evaluated from food records.  
Results: The CD patients had minor oral manifestations at a median of nine years after their 
childhood diagnosis and the most common was angular cheilitis, which affected six patients and 
one control, but was not statistically significant (P=0.0984). CD with perianal abscessing disease 
correlated to orofacial findings (P=0.0312). Most of the patients had normal otorhinolaryngological 
findings. Subjects with oral lesions had lower mean HRQoL scores than subjects without oral 
findings and the differences were clinically but not statistically significant. Oral manifestations 
were not associated with differences in energy intake. 
Conclusions: Oral manifestations in adult patients with pediatric onset CD were mild and were not 
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Crohn´s disease (CD) is a chronic inflammatory disease that typically presents in the terminal ileum 
and colon, but can affect any part of the digestive tract, including the mouth. The reported 
prevalence of oral manifestations in CD varies widely and ranges from 0.5% to 80%[1-3]. These 
manifestations may coincide with the intestinal symptoms of CD, or precede them, but there are 
very few systematic studies at different stages of the disease. Furthermore, we are not aware of 
reports on the otorhinolaryngological health of CD patients.   
Orofacial granulomatosis (OFG) is an uncommon chronic inflammation that affects the oral cavity 
and the area around the mouth without intestinal involvement. Oral lesions in CD and OFG cannot 
be clinically or histologically distinguished. OFG patients may develop a symptomatic gut disease 
and clinicians have debated whether OFG is an oral manifestation of CD or a separate inflammatory 
disorder[4,5]. Our previous follow-up study of 29 patients with pediatric onset OFG found that, 
72% developed symptomatic gut disease within a median of 3.1 years[6]. OFG patients had plenty 
of oral lesions, but stated that they were mostly asymptomatic. A prospective study of pediatric 
patients with suspected CD found oral pathology in approximately 40% of the patients and these 
mostly went unnoticed before they were examined[7]. This encouraged us to evaluate the presence 
of oral manifestations in pediatric CD patients when they reached adulthood.   
This was a comprehensive cross-sectional study that focused on adult patients with pediatric onset 
CD who attended Helsinki University Hospital, Finland, for a follow-up visit. Young adults risk 
dropping out of routine check-ups because of the transition to pediatric to adult care [8] and that is 
why we chose to study this age group. A dentist and an otorhinolaryngologist examined the patients 
and the age and sex matched healthy controls and laboratory tests and nutritional evaluation were 
also carried out.  
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The aim of this study was to examine the oral and otorhinolaryngological lesions and symptoms in 
pediatric onset CD patients when they reached adulthood, evaluate the factors associated with oral 
manifestations and study the long-term oral health outcomes of CD patients.    
 
Materials and Methods  
This follow-up study was performed between September and December 2016. The study cohort 
comprised Finnish-speaking adult patients from the Helsinki capital region who were born between 
1987-1997 and diagnosed with CD in childhood after the year 2000 at the Helsinki University 
Children´s Hospital, Finland. The diagnosis of CD fulfilled the diagnostic Porto criteria, including 
endoscopies with biopsies and small bowel imaging[9]. Of the 63 patients we were able to trace, 18 
patients could not be contacted and 21 patients declined to participate for unknown reasons, as the 
ethics committee guidelines state that that we are not allowed to ask people why they don’t wish to 
take part. We also traced 97 healthy controls from the Population Register Centre - approximately 
four for each patient who agreed to take part - and these were matched for age and sex, but no 
inclusion or exclusion criteria were applied to the selection. Of these, 47 could not be contacted, 27 
declined to participate in the study and one did not respond either way, with these rates being 
similar to CD patients. The patients and their controls were recruited by sending them a mailed 
invitation and following this up with a phone call from the study nurse. The final numbers were 24 
in the CD group and 22 in the control group. 
 
Study visits  
Patients and controls were examined using a structured schema by a dentist (HA, LA or US) and an 
otorhinolaryngologist (AH). Digital photographs of the mouth were taken to illustrate the findings 
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and the orofacial findings were carefully recorded using the oral disease activity score chart for 
OFG[10]. On the score chart each site in the orofacial area involved was scored individually for 
activity and type of lesion, with the total score indicating global severity and the maximum total 
score being 87. The presence of cobblestoning lesions, fibrous banding/scarring, facial swelling and 
erythema and staghorning of oral mucosa were recorded.  The oral examination was carried out in a 
dental unit using a dental mirror, dental and periodontal probes, fiber optic illumination and 
appropriate dental lighting. Radiographs were not taken. The patients’ oral hygiene levels were 
assessed by using the Silness-Löe plaque Index[11]. The periodontal condition was assessed by 
measuring the depth of the periodontal pockets and the presence of bleeding after probing all the 
teeth. Dental caries were recorded with the decayed, missing, and filled teeth (DMFT) index[12]. 
The otorhinolaryngological examination included fiberoscopic laryngoscopy. 
 
Questionnaires  
Subjects filled in questionnaires about their general health, medication, special diets and lifestyle 
habits. Their health-related quality of life (HRQoL) was evaluated using the 15D questionnaire, a 
generic, standardized, self-administered measure of HRQoL for individuals aged 16 years or older. 
The 15D includes the following 15 dimensions: breathing, mental function, speech 
(communication), vision, mobility, usual activities, vitality, hearing, eating, excretion, sleeping, 
distress, discomfort and symptoms, sexual activity and depression. There is one question for each of 
the dimensions and each one has five possible responses. The 15D can be used as a profile 
instrument, but it can also provide a single index 15D score, ranging from a maximum of one when 
there are no problems on any dimension to the minimum of zero when the subject has died[13]. A 
change of 0.015 in the total 15D score is considered to be the minimum clinically important 
difference that a patient can feel[14].  
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Patients were also asked to evaluate the severity of their gut symptoms, and possible orofacial 
symptoms at the time of the examination, on a Likert-scale with seven response points, where one 
represented no symptoms and seven represented very difficult symptoms. Patients were asked to 
keep a food diary for three days before the scheduled appointment and these were checked by a 
trained nurse for any possible omissions and controversial comments. A dietitian recorded the food 
diaries by using special food software (AivoDiet, Aivo Finland Oy, Turku, Finland), which makes 
use of a national database of foods. The food diary also asked about dietary supplements and the 
compositions of these supplements were checked with the manufacturers. We also recorded whether 
the patients and the controls consumed any foods containing cinnamon or benzoic acid[15-17], 
because both of these have been reported to be common allergens when patch testing patients with 
OFG. Information about the therapies that the patients received were collected from their patient 
charts.  
 
Laboratory investigations  
Subjects were asked to provide a stool sample so that we could measure their fecal calprotectin in a 
routine clinical laboratory using a quantitative enzyme immunoassay (PhiCal Test, Calpro AS, 
Oslo, Norway). Values of <100 μg/g were considered to be normal[18,19]. Stool samples were 
collected from 43 subjects: 24 patients and 19 controls.  
Blood samples were collected from all subjects and the laboratory tests included C-reactive protein 
(CRP), the erythrocyte sedimentation rate (ESR), hemoglobin, blood leukocyte counts and anti-




The Ethics Committee of Helsinki University Hospital approved the study protocol and the subjects 
signed an informed consent form.  
 
Statistical analyses  
The non-parametric Mann-Whitney and Spearman´s correlation tests and Fisher’s exact test were 
used to investigate the associations between the variables. The groups were compared using the 
independent samples t-test or Mann-Whitney U test as appropriate. Statistical analyses were 
performed using GraphPad Prism 7 for Windows (GraphPad Software, Inc, San Diego, USA) and 
SPSS software version 22 (SPSS Inc., Chicago, Illinois, USA). Differences were considered 
significant when the P-value was <0.05.  
 
Results  
The study group comprised 24 patients with CD and 22 healthy controls matched for age and sex 
and their background characteristics are shown in Table 1. The CD patients had a median age of 
22.0 years (range 19.3-27.5 years) and the median age of the controls was 21.8 years (range 18.9-
28.9 years). The median duration of the CD patients´ follow-up from their primary diagnosis was 
9.0 years (range 4.7-15.2 years). Concomitant diseases were recorded in 15 (62.5%) of the CD 
patients and four (18.2%) of the controls (Table 1).  
 
Oral findings 
We found that 19 (41.3%) of the 46 participants had self-reported oral symptoms. Of the 24 CD 
patients, 14 (58.3%) reported oral symptoms at some point during their follow-up. At the time of 
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the study, the patients´ subjective evaluation of their own orofacial symptoms varied from a score of 
one for no symptoms (n=28) to four for moderate symptoms (n=2) and the median score was one 
for both the patients and the healthy controls (P=0.1270, Table 2). The subjects´ own evaluation of 
their oral symptoms did not correlate with the oral findings observed during the study visit, as the 
subjective evaluation varied in different people (Spearman´s r=0.1457, n=46, P=0.3338).  
The patients and controls had very few oral findings (Table 2) and the total scores for OFG, 
according to the oral disease activity score chart, ranged between zero and three (median 0). Of the 
46 subjects, 10 (21.7%) had findings in the orofacial area and these comprised eight (33.3%) of the 
24 patients with CD and two (9.1%) of the 22 controls. All the oral findings were recorded as mild. 
The most common oral finding was angular cheilitis in seven (15.2%) of the total cohort of 46 
subjects, including six with CD, but no statistical significance was reached between the controls and 
CD patients (P=0.0984). The oral mucosa, gingival sulcus, gingiva and soft palate were affected in 
one or two patients each, most with CD, as shown in Table 2. None of the study subjects had 
cobblestoning, linear ulcers, fibrous banding/scarring, facial swelling and erythema or staghorning 
of the oral mucosa. In addition, none of the patients had findings in their upper or lower lip, lower 
gingiva, tongue, floor of the mouth, hard palate or pharynx. Four CD patients who had oral findings 
at the time of the study had not reported any orofacial symptoms.  
We did not observe any significant correlation with age and the total score of the orofacial findings 
in the whole cohort (Spearman´s r=-0.2407, n=46, P=0.1070) or just among the CD patients 
(Spearman´s r=0.2348, n=24, P=0.2695). In addition, the follow-up time from the primary diagnosis 
of CD did not correlate with the total score (Spearman´s r=-0.3059, n=24, P=0.1460). However, 
patients with a history of perianal abscesses had more oral manifestations than patients without 




Therapies provided for CD 
The therapies that were being provided for CD at the time of the study are shown in Table 3. Of the 
24 CD patients, 12 (50.0%) were being treated with biological drug therapy and 17 (70.8%) had 
received biologicals at some point during their follow-up. There were no differences between the 
oral findings of CD patients who did or did not receive biologicals (Spearman´s r=0.01407, n=24, 
P=0.9480). Three patients had not received any medication for CD at the time of the study and there 
was no increase in their oral findings compared to the other CD patients (P=0.9481).  
The CD patients´ subjective evaluation of their bowel-related symptoms varied between one for no 
symptoms (n= 3) to four for moderate symptoms (n=3), with a median score of two. Their self-
reported activity for gut symptoms was not associated with more oral findings or a higher total 
score for orofacial findings (Spearman´s r=0.1618, n=24, P=0.2827).  
 
Dental status 
The oral hygiene level was fair (plaque index ≥1.0) in 14 (30.4%) of the 46 subjects (median 0.5, 
range 0-2.7) and untreated dental decay was found in 17 (37.0%) subjects. Of the 46 subjects, only 
seven (15.2%) were cavity free with a DMFT score of zero. All the subjects had gingivitis, except 
for two, and 10 (21.7%) had periodontal pockets than were at least 4mm. There were no statistically 
significant difference in the dental findings between the CD patients and controls. None of the 
dental findings correlated statistically significantly with the total score of oral manifestations.  
 
Otorhinolaryngological status  
We found that the otorhinolaryngological findings were very minor. Of the 46 subjects, there were 
13 (28.3%) who had a noticeable adenoid, including six with CD. In three of the CD subjects this 
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was a mucous adenoid. Eight (17.4%) of the 46 subjects had erythema and four (8.7%) had swelling 
of the nasal concha. Nasal polyps, atrophy of the nasal conchae or septum perforation were not 
found. However, 11 (23.9%) of the total cohort reported chronic nasal obstruction and this was as 
common among the six CD patients as the five controls (P=>0.9999).  
None of the subjects had swelling of the major salivary glands. Six subjects had undergone a 
tonsillectomy and a tonsillotomy, while the others had grade I-II tonsils. One subject had 
tonsilloliths as a sign of chronic tonsillitis. Slight enlargement of the cervical lymph nodes was 
found in three (6.5%) of the 46 subjects, but there were no signs of an acute infection in the 
pharynx. Nasofiberoscopy was successful in all but one subject and there was one case of each of 
the following: erythema in the vocal cords and erythema and swelling of the arytenoid cartilages. 
Three subjects had cerumen, which complicated our inspection of their ears, but all the other 
subjects had normal findings in their ears.  
 
Health-related quality of life 
The mean HRQoL scores were lower in patients with CD – with a mean of 0.920 out of a possible 
score of one - compared with 0.951 for the controls. The difference was regarded as clinically 
important[14], but not statistically significant. There were slight differences between the groups in 
the dimensions of vision, breathing, sleeping, speech, excretion, usual activities, distress, 
depression, discomfort and symptoms and vitality, as shown in Supplementary Figure 1.  However, 
the only statistically significant difference between the CD patients and controls was seen in the 
excretion dimension (P=<0.01). When we compared the subjects with oral findings, defined as a 
total OFG score of ≥1, to those without them, with a total OFG score of zero at the time of the 
study, this revealed that subjects without oral findings fared better on every HRQoL dimension we 
measured, except hearing, eating and vitality. However, we only found a statistically significant 
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difference in breathing (P<0.05), with subjects without oral findings having better scores. The 
disease duration in CD patients did not significantly affect HRQoL.  
 
Laboratory investigations 
Twelve (26.1%) of the subjects had elevated CRP levels over 3 mg/L, but the patients with CD did 
not have higher CRP levels than the controls, as both of the median levels were 1mg/L (P=0.1639). 
The CRP values did not correlate with the number of orofacial symptoms, which would have been 
indicated by higher OFG total scores (Spearmans r=-0.01183, n=43, P=0.9378). ESR was above the 
reference values in seven (15.2%) of the 46 subjects, with a median of 5 mm/h (range 2-66 mm/h), 
and did not differ markedly between the patients with CD and the controls, with medians of 8 and 
12 mm/h respectively (P=0.0631). Higher ESR correlated with higher total scores for orofacial 
findings (Spearman´s r=0.3363, n=43, P=0.0239). Blood leukocyte counts did not differ between 
the CD patients and controls (median 6.9 and 6.9 respectively, P=0.5744) and did not correlate with 
orofacial symptoms (Spearman´s r=0.2133, n=43, P=0.1546).  
We found that seven (15.2%) of the 46 subjects had elevated levels of anti-Saccharomyces 
cerevisiae antibodies A (ASCAbA) (median titre 30 U/ml, range 23-156) and six of them had CD. 
Elevated levels of ASCAbG were found in six (13.0%) subjects (median 30 U/ml, range 27-63), 
including four who had CD. Elevated ASCAbA or ASCAbG levels did not significantly correlate 
with the subjects´ total score of oral findings (Spearman´s r=-0.1012, n=46, P=0.5033 and 
Spearman´s r=0.07197, n=46, P=0.6346 respectively).  
Fourteen (32.6%) of the 43 subjects who provided a stool sample had elevated (≥100 µg/g) values 
of fecal calprotectin (median 308, range 100-2488 µg/g). As expected, patients with CD (median 
121.5, range 6-2488 µg/g) had significantly higher calprotectin values than the controls (median 19, 
range 3-174 µg/g) (P=0.002), but these were not associated with more oral findings in CD patients 
14 
 
(Spearman´s r=0.1819, n=24, P=0.3948). One healthy control without gut symptoms had fecal 
calprotectin above the normal range (174 µg/g), but this was back to normal in a couple of weeks 
and further tests were considered unnecessary.   
 
Nutrition  
Ten CD patients (41.7%) and seven controls (31.8%) reported avoiding some food items and 
avoiding lactose was the most common (n = 7). Two other patients (8.3%) and one control (4.5%) 
avoided milk and milk products for other health-related reasons and one patient (4.1%) and one 
control (4.5%) avoided wheat. Four patients (16.7%) and four controls (18.2%) reported food 
allergies. In addition, three patients (12.5%) and five controls (23.8%) were either vegetarians or 
avoided red meat. The differences between CD patients and their controls were not statistically 
significant. All but three of the 46 subjects had eaten food containing benzoic acid, which is a 
common allergen that is reported when testing OFG patients, either in its natural forms or as 
additive. This varied varying from an average of 0.33 to six times per day according their three-day 
food diaries. We did not find any association between benzoic acid consumption and oral findings 
(p=0.734, one-way ANOVA). In addition, the proportion of subjects who consumed cinnamon did 
not differ between the CD patients (37.5%) and the controls (31.8%, p = 0.686). We saw no 
difference in energy and nutrient intakes between the patients and controls: the median intakes of 
carbohydrates, fiber and folic acid were lower than recommended in the patients and controls and 
the median intakes of saturated fatty acids were higher than recommended [20]. CD patients 
reported higher vitamin D intakes than the controls (median intake 9.7 vs. 5.2 µg per day) and this 
difference was close to statistical significance (p = 0.068, Mann-Whitney U test, Supplementary 
Table 1). The oral findings did not correlate with energy intake (rs = 0.082, p = 0.590), whereas 
those with moderate gastrointestinal symptoms received less energy than those with mild or no 
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symptoms (22.9 vs 33.2 kcal/kg/day, p = 0.042, t-test). However, we saw no statistical difference in 
their body mass indexes, which were a median of 28.1 in the symptomatic subjects and a median of 
23.6 in the subjects with mild or no symptoms (p = 0.150).  
 
Smoking and alcohol consumption 
Of the 46 participants, three (6.5%) reported smoking cigarettes, one (2.2%) used an electronic 
cigarette and seven (15.2%) reported taking snuss, which is a moist powder tobacco that is placed 
under the upper lip for extended periods of time. Taking snuss correlated with more orofacial 
findings and a higher total score (Spearman´s r=0.3343, n=46, P=0.0232), although the oral findings 
that were clearly caused by taking snuss, for example damage to the gingival mucosa in the exact 
place where the subject kept the snuss, were excluded from the total score count. However, smoking 
did not correlate with more orofacial findings (Spearman´s r=-0.1472, n=46, p=0.3288). Alcohol 
consumption was modest in all of the subjects.  
 
Discussion 
Oral findings  
In previous publications the prevalence of oral manifestations in CD has varied widely and has 
ranged between 0.5% and 50% in adult cohorts[1-3] and 10% to 80% in pediatric CD patients [21]. 
These wide variations can partly be explained by the often subtle character of lesions, the difficulty 
in noticing lesions if they are not the primary reason for the examination and the fact that the 
inclusion of non-specific lesions may have varied between studies. More than a third of the 24 
pediatric onset CD patients in our study had oral lesions at the time of the study and these were 
mostly isolated and recorded as mild. The patients were also receiving good therapeutic control for 
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their gut disease during the study period, which may have explained the reasonable number of oral 
lesions. Thus, it seems that pediatric CD only confers a modest risk of oral lesions at adult age, 
although our study showed that oral lesions were more frequent in pediatric onset CD than in adult 
onset CD. However, oral lesions were more common in the CD patients than the controls, affecting 
one-third and one-tenth, respectively. 
  
A study by Laranjeira et al of 113 adult patients with inflammatory bowel disease (IBD) - either 
ulcerative colitis or CD - and 58 controls, found that oral mucosa lesions increased over the course 
of the disease[22]. In our cohort, the length of follow up ranged from 4.7 to 15.2 years after the CD 
diagnosis and the time period was not associated with oral findings. In the Laranjeira et al study, 
patients in the clinically active phase of IBD were the most affected[22], but this may not have been 
the case in children[1]. Our study of pediatric onset CD patients who had reached adulthood showed 
no correlation between the oral findings and the subjective evaluation of the severity of gut 
symptoms in CD or with fecal calprotectin levels, a surrogate marker for intestinal inflammation. In 
our previous study of 29 pediatric onset OFG patients, including 72% who had CD, there was no 
association between fecal calprotectin and orofacial findings [6]. This suggests that oral 
inflammation and intestinal inflammation are driven by different, but uncharacterized, factors. 
  
The oral lesions that are observed in CD patients are typically divided into disease-specific and non-
specific lesions. Specific lesions result from the same disease process as CD in the gut, namely 
granulomas that can be identified by histology. These specific lesions include swelling of the lips, 
cheeks and gingiva, cobblestoning of the mucosa, deep linear ulcers and mucosal tags[1,21], which 
are also typical lesions in OFG. Non-specific lesions are reactive lesions without granulomas[21]. 
Patients with CD often suffer from aphthous ulceration, angular cheilitis, lip fissuring and 
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gingivitis, but these are not specific to CD[21]. In our cohort, disease-specific lesions were not 
found in any of the subjects and non-specific angular cheilitis was the most frequently seen oral 
lesion. A 2010 review stated that disease-specific oral manifestations are particularly common in 
children with CD[1]. Interestingly, it has been suggested that if oral manifestations are present when 
children are diagnosed with CD then this might be a marker for a severe CD phenotype[1]. 
However, this observation needs to be further examined. A specific risk factor for oral findings in 
adulthood was a history of perianal abscesses, which is an indicator of a complicated disease 
subtype[9]. Others have reported such an association between CD and oral findings[1,2,23]. 
The spectrum of oral lesions that have been reported in CD patients varies widely. The most 
common lesion that has been reported is cobblestoning of the buccal mucosa, followed by linear 
ulcers[24], while the lips[25] and angle of the mouth[26] have been reported to be the most 
frequently affected sites. In reviews on pediatric patients, mucogingivitis[1] and oral ulceration[21] 
were reported to be the most common oral lesion. In our cohort, angular cheilitis was the most 
frequently seen oral lesion, with other lesions being sporadic. In our previous study, the most 
common site for orofacial lesions in OFG patients was the buccal mucosa, with almost 90% of 
patients showing some issues in this area. However, the most common individual oral manifestation 
was swelling of the lower lip, which was present in about 65% of our patients[6]. 
Oral findings are not usually problematic from a clinical point of view, as they may be 
asymptomatic and they often resolve over time[1]. On the other hand, a number of patients can have 
very troublesome symptoms that cause pain and functional difficulties in relations to speaking and 
eating[21] and these require medical intervention or even surgery[2]. In our cohort, oral 
manifestations at the time of the study were mild, or at most moderate, and did not seem to have a 
significant effect on the subjects´ quality of life. Surprisingly, oral lesions did not affect the eating 
score of any of the subjects in our study. The HRQoL in CD patients and controls only showed a 
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statistically significant difference with regard to excretion functions. CD patients also had lower 
HRQoL scores in other dimensions, but statistical significance was not reached, which can partially 
be explained by the relatively small subject groups. Our study was one of the first studies reporting 
HRQoL in pediatric onset CD patients at adult age.  
Treatment 
Earlier publications have showed that oral manifestations are most evident when the gut disease 
first presents itself and the treatment that the patient receives for this also seems to have an effect on 
oral lesions in CD patients[21]. In most cases, managing the underlying intestinal disease is 
sufficient to treat the oral lesions, but variations in the ways that these patients are described and 
classified makes it hard to compare different patient cohorts. The historical oral lesions that were 
reported in our study had not received any specific treatment as the patients had just been treated for 
the gut disease. Half of the patients were on biologicals at the time of our study, and more than two-
thirds had received them at some point for their gut disease, but this did not seem to affect the 
orofacial manifestations. We need to examine this finding further to see what it means: does it mean 
that the biologicals that are administered to treat gut disease are also effective in treating oral 
lesions or does it mean that that severe gut diseases that require biologicals are not associated with a 
larger number of oral lesions?  
Our previous study of pediatric OFG patients demonstrated the varying severity and need for 
treatment of oral lesions, as 40% of the 29 subjects with CD who were receiving systemic 
medication did not need topical therapy. However, approximately half of the patients who had CD 






To our knowledge, otorhinolaryngological findings in CD patients have not been reported in detail 
before. Most of our subjects had normal findings during the otorhinolaryngological examination, 
which included fiberoscopy of the nasopharynx and larynx. Signs of acute or chronic inflammation 
were not detected, which strengthens the obvious assumption that inflammatory changes in CD are 
restricted to the gastrointestinal tract without excess otorhinolaryngological comorbidity. 
Empirically, CD patients seem to have suffered quite commonly from nasal obstruction, but in our 
study neither the patients´ own evaluation of any nasal obstruction, nor the clinical findings of the 
nasal cavity and nasal conchae, differed significantly between the CD patients and controls. In 
addition, no nasal polyps that caused nasal obstruction were detected. A detectable adenoid was as 
common in the CD patients as in the controls, but interestingly all patients with a mucous adenoid 
had CD.   
 
Blood markers 
In our earlier study of 29 patients with pediatric onset OFG, ASCAbA appeared to be a possible 
marker for the development of CD in OFG patients[6]. In this current study, ASCAbA did not 
correlate with oral findings in pediatric onset adult CD patients in a statistically significant manner,  
but overall there were fewer oral findings in this study cohort.  
Only a small percentage of patients had elevated CRP levels and these did not correlate with 
orofacial findings, unlike elevated ESR, which was found in one-sixth of the patients. However, in 
our previous study of 29 patients with pediatric onset OFG[6], elevated CRP or ESR levels were not 
connected to oral disease activity[27]. Elevated ESR and CRP have previously been connected to a 
higher risk of CD in OFG patients[15], but OFG has not been associated with any significant 





Patients with CD have poor nutritional absorption and their dietary intake of several nutrients may 
be lower than recommended, due to them self-selecting an elimination diet in an attempt to relieve 
their symptoms. This means that patients are at nutritional risk[29]. In our study, the median intakes 
of carbohydrates, fiber and folic acid were lower in both the patients and controls and the median 
intakes of saturated fatty acids were higher than recommended [20] (Supplementary Table 3). There 
has been much debate about the role of vitamin D in immunology in the press and social media, 
which was probably reflected in the fact that the patients received more vitamin D than the controls. 
The mild oral findings, or perceived oral symptoms, were not associated with energy intake, 
whereas the gut symptoms seemed to be associated with eating less. However, this was not reflected 
in the body mass index of the subjects, suggesting underreporting in the food records, which is a 
common finding when studying nutrition[30]. 
 
Strengths and limitations 
We believe that the number of patients that were included was a limitation in our study, even 
though they were collected from a large population of 1.1 million inhabitants. It seems that young 
adults have college or work obligations that get in the way of them taking part in studies and this is 
a challenge when it comes to recruiting study subjects. A valid strength of our study was that it was 
comprehensive and included a dental and otorhinolaryngological examination, laboratory tests, 
nutritional aspects and HRQoL measurements. Including a control group in the study was also a 
valid strength of this study. To minimize inter-observer variations, patients were examined in 
parallel by a designated otorhinolaryngologist and a dentist using a structured schema. However, 
the dental examination was provided at no cost, which might have encouraged people with poorer 
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There are many kinds of orofacial manifestations in CD patients and they also vary between 
individuals. Oral manifestations do not seem to increase during the course of the gut disease and 
they seem to be inactive when the gut disease is under good therapeutic control. The possible 
exacerbation of oral lesions during the active phases of the gut disease need to be further examined. 
Dental findings did not correlate with oral lesions in our study and otorhinolaryngological 
comorbidity was not found. Oral manifestations were more likely to be seen in CD patients with a 
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Table 1. Background characteristics of the study population 
Number of subjects 46 
Patients with CD 
     Male 
24 (52.2%) 
14 (58.3%)  
Healthy controls 22 (47.8%) 
     Male 11 (50.0%) 
Age in years, median (range) 
 At Crohn´s disease diagnosis 13 (8-16) 
    At study appointment  
        Patients with CD 22 (19-28) 
        Healthy controls 22 (19-29) 
Diagnoses 
 CD 24 
 Previous surgery 5 
 Fistulazing perianal disease 7 
Concomitant diseases, CD patients  
    Pollen and animal allergies or atopy 8 
    Depression 3 
    Psoriasis 2 
    Asthma 1 
    Migraine 1 
    Complement C4b deficiency 1 
    Ikhthyosis 1 
    Disorders of vitamin D metabolism 1 
    Deficit in attention, motor control and perception 1 
Concomitant diseases, controls  
 Rheumatoid arthritis 2 
    Asthma 1 
    Hypothyreosis 1 
    Rhinitis chronica 1 
    Acne 1 
Duration of CD in years, median (range) 
Time between CD diagnosis and study 9.0 (4.7-15.0) 
CD= Crohn´s disease  
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Table 2. Site and type of oral manifestations in patients with CD and controls and the participants’ 
own evaluation of their orofacial symptoms at the time of the study.  
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  All CD Controls 
Number of study subjects 46 24 22 
Lips 0 0 0 
  Lower lip 0  0 0 
  Upper lip 0 0 0 
  Angular cheilitis* 7  6  1 
Oral mucosa 1  1 0 
    Ulceration 1 1 0 
    Fissures 1 1 0 
  Buccal sulcus 2  2 0 
    Erythema 1 1 0 
    Ulceration 1 1 0 
Gingiva 2  1 1 
    Erythema 2 1 1 
Tongue 0 0 0 
Floor of the mouth 0 0 0 
Soft palate 1  1 0 
   Nodules 1 1 0 
Hard palate 0 0 0 
Pharynx 0 0 0 
Total score** median (range) 0 (0-3) 0 (0-3) 0 (0-1) 
Participants own evaluation of oral symptoms*** 
Median (range) 
1 (1-4) 1(1-4) 1(1-4) 
CD= Crohn´s disease 
* P=0.0984 when compared between patients with CD and controls 
**Oral disease activity score chart for orofacial granulomatosis 
***Likert scale from 1(no symptoms)  to 7 (difficult symptoms) 
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Number of subjects 24 
Systemic treatment  
Biological drug therapy 12 (50.0%) 
        anti-TNF alfa therapy 11 (45.8%) 
        anti-IL12/23 antibody 1 (4.2%) 
Azathioprine/6-merkaptopurine 
       as monotherapy 





Methotrexate (combined with a biological drug) 
5 (20.8%) 
1 (4.2%) 
No medication for CD 3 (12.5%) 
CD= Crohn´s disease  
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Supplementary Figure 1. Health-related quality of life in CD patients and controls, as evaluated by 
the 15D questionniare.  
 
 
*Move=mobility, See=vision, Hear=hearing, Breath=breathing, Sleep=sleeping, Eat=eating, Speech=speech 
(communication,) Excret=excretion, Uact=usual activities, Mental=mental function, Disco=discomfort and 













    










Energy (kcal) 2334.0 (1849.2-2658.9) 2328.5 (1958.4-2575.9) 0.895   
Protein (g) 100.1 (80.1-140.0) 78.3 (68.8-109.4) 0.104  
Protein (E%) 17.5 (15.5-22.1) 14.3 (12.4-18.4) 0.079 10-20 
Carbohydrates (g) 247.3 (184.9-315.4) 254.2 (208.4-303.0) 0.860   
Carbohydrates (E%) 40.9 (36.0-46.4) 43.5 (40.0-50.4) 0.235 45-60 
Fat (g) 97.9 (71.4-106.5) 87.9 (70.6-113.1) 0.758   
Fat (E%) 36.6 (31.2-41.4) 35.5 (30.8-41.3) 0.598 25-40 
SAFA (g) 28.6 (20.7-37.1) 30.9 (20.9-41.1) 0.598   
SAFA (E%) 11.7 (9.3-14.0) 11.2 (8.9-15.0) 0.947 > 10 
MUFA (g) 33.6 (25.7-37.1) 29.6 (21.2-43.4) 0.676   
MUFA (E%) 12.9 (10.5-14.1) 12.0 (9.0-16.2) 0.509 10-20 
PUFA (g) 13.7 (11.9-8.0) 14.2 (9.4-19.4) 0.783   
PUFA (E%) 5.9 (4.6-6.8) 6.0 (4.1-7.6) 0.775 5-10 
Sucrose (g) 50.6 (18.8-62.5) 42.3 (31.4-54.4) 0.509   
Sucrose (E%) 8.4 (4.4-11.8) 7.4 (6.0-8.8) 0.792 >10  
Fiber (g) 17.4 (13.5-22.4) 20.1 (15.9-25.9) 0.191 25-35 
Vitamin A (µg) 703.0 (461.4-854.1) 747.8 (452.3-907.6) 0.826 900 700 
Vitamin D (µg) 9.7 (6.1-15.1) 5.2 (3.7-12.2) 0.068 10 
Vitamin E (mg) 12.0 (10.1-16.4) 12.0 (9.4-14.7) 0.416 10 8 
Vitamin K (µg) 121.4 (86.0-199.9) 101.9 (70.8-132.7) 0.129   
Vitamin C (mg) 112.9 (56.9-209.4) 95.9 (59.3-152.3) 0.598 75 
Thiamine (mg) 1.3 (0.9-2.0) 1.1 (1.0-1.6) 0.350 1.4 1.1 
Riboflavin (mg) 2.2 (1.4-3.9) 1.8 (1.4-2.2) 0.180 1.6 1.3 
Niacine (mg) 50.6 (31.0-65.6) 39.3 (29.3-55.2) 0.180 19 15 
Pyridoxine (mg) 2.9 (1.7-4.6) 2.1 (1.8-3.9) 0.403 1.6 1.3 
Vitamin B12 (µg) 6.8 (4.6-10.8) 5.0 (3.3-7.3) 0.104 2.0 
Folic acid (µg) 271.1 (214.8-365.3) 277.0 (228.2-404.0) 0.692 300 400 
Magnesium (mg) 349.9 (260.6-494.0) 363.8 (308.7-447.7) 0.843 350 280 
Calcium (mg) 1011.2 (727.5-1306.8) 957.3 (772.7-1217.1) 0.644 800 
Iron (mg) 12.0 (9.9-15.6) 13.7 (11.8-15.8) 0.244 9 15 
Potassium (mg) 3499.0 (2838.5-4428.8) 3533.1 (3028.6-4147.6) 0.692 3500 3100 
Phosphorus (mg) 1441.7 (1172.9-2064.6) 1457.7 (1186.1-1805.0) 0.792 600 
Selenium (µg) 83.3 (66.4-115.2) 60.4 (52.1-105.8) 0.079 60 50 
Zinc (mg) 12.3 (9.7-17.8) 12.1 (10.3-16.8) 0.930 9 7 
RNI= recommended nutrient intake, SAFA=saturated fatty acids, MUFA=monounsaturated fatty acids, 
PUFA=polyunsaturated fatty acids 
*Mann-Whitney U test 






     
